A smarter Europe

IMMUNOCLUSTER-2

Introduction of a clinical study with an advanced cellular aHyC at interregional level
Duration
24
months
Start date
September 2023
End date
August 2025
Partner
6
Budget
749.059,60 €
ERDF Budget
599.247,68 €
Progress
5%
 
The project
Project summary

Policy objective: PO1 - A more competitive and smarter Europe by promoting innovative and smart economic transformation and regional ICT connectivity

Specific objective: SO1 - Developing and enhancing research and innovation capacities and the uptake of advanced technologies

Typology: capitalization project

IIMMUNOCLUSTER-2 project addresses the strengthening of cross-border cooperation to improve the quality of life of the population.

Objectives
  • The general goal of the project is the initiation of a clinical trial for the treatment of triple negative breast cancer (TNBC) with a cell-based vaccine (aHyC) at the interregional level, to create the possibility of providing personalized advanced cancer therapies in an accessible and affordable way, to develop and improve innovation capabilities, and enabling the introduction of advanced technologies.
  • Considering the existing situation, the project will promote innovation and improve technology transfer to SMEs, strengthen cooperation between innovative companies, research and healthcare institutions, and allow the capitalization of the results achieved in the previous project INTERREG ITASLO 2014-2020 Immuno-Cluster in a new integrated framework at regional level.
Output

The main project outputs will be available soon.

Partner

Celica, biomedicinski center, d.o.o
Onkološki inštitut Ljubljana
VivaBioCell S.p.A
Università degli studi di Udine
Azienda Sanitaria Universitaria Friuli Centrale
Zavod Republike Slovenije za transfuzijsko medicino

News and Events

Contacts

Celica, biomedicinski center, d.o.o

Tehnološki park 24 - 1000 Ljubljana
prof. Helena Haque Chowdhury
helena.chowdhury@celica.si
0038 641 334 097
Share this project